Read-Gene S.A. (WSE:RDG)

Poland flag Poland · Delayed Price · Currency is PLN
4.040
-0.260 (-6.05%)
Last updated: Jun 3, 2025
-14.77%
Market Cap 52.82M
Revenue (ttm) 14.49M
Net Income (ttm) -591.04K
Shares Out 11.79M
EPS (ttm) -0.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 133
Average Volume 267
Open 4.260
Previous Close 4.300
Day's Range 4.040 - 4.260
52-Week Range 3.800 - 6.660
Beta 0.68
RSI 57.21
Earnings Date May 9, 2025

About Read-Gene

Read-Gene S.A. engages in the detection, prevention, and treatment of various types of cancer. Its activities include chemoprevention, clinical tests, and genetic tests. Chemoprevention is the use of natural or synthetic substances to stop, reverse, or delay the process of developing cancer. The company conducts clinical trials in cancer patients; and provides genetic tests and genetic-oncological consultations to all patients for the most common cancers, such as breast, ovary, prostate, stomach, large intestine, and breast cancer. Read-Gene S.... [Read more]

Industry Biotechnology & Medical Research
Sector Healthcare
Founded 2005
Employees 22
Stock Exchange Warsaw Stock Exchange
Ticker Symbol RDG
Full Company Profile

Financial Performance

In 2024, Read-Gene's revenue was 12.85 million, an increase of 26.62% compared to the previous year's 10.15 million. Losses were -995,997, -26.03% less than in 2023.

Financial Statements

News

There is no news available yet.